CA2926478C — Rho kinase inhibitors
Assigned to Kadmon Corp LLC · Expires 2022-05-24 · 4y expired
What this patent protects
The invention relates to compounds that inhibit ROCK2 which are useful for the treatment of an autoimmune disorder, wherein the autoimmune disorder is psoriasis, atopic dermatitis, eczema, or graft-versus-host disease (GVHD), and wherein the compound that inhibits ROCK2 is a comp…
USPTO Abstract
The invention relates to compounds that inhibit ROCK2 which are useful for the treatment of an autoimmune disorder, wherein the autoimmune disorder is psoriasis, atopic dermatitis, eczema, or graft-versus-host disease (GVHD), and wherein the compound that inhibits ROCK2 is a compound of the formula )0(XII: or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.